Skip to main content

An update on an incident involving one of our systems

Hide
Quest Diagnostics

Prevalence and Co-Detection Rates of SARS-CoV-2, Influenza, and Respiratory Syncytial Virus: A Retrospective Analysis

Prevalence and Co-Detection Rates of SARS-CoV-2, Influenza, and Respiratory Syncytial Virus: A Retrospective Analysis

Authors: Pratt GW, Wong CL, Rao LV

Citation: APMIS. 2025 Feb 27;133(3):e70010. doi:10.1111/apm.70010

Specialties: Infectious disease, Immunology

Related content

Publication
Risk of and duration of protection from SARS CoV 2 reinfection assessed with real world data
Conference Presentation
Coinfection Rates of SARS-CoV-2, Influenza, and Respiratory Syncytial Virus
Publication
SARS-CoV-2 Spike-Protein Targeted Serology Test Results and Their Association With Subsequent COVID-19-Related Outcomes
Conference Presentation
Comparison of Cepheid, Roche, and LDT platforms for COVID-19 and influenza testing
Test FAQ
Influenza A (H5) Virus RNA, Qualitative Real-Time PCR, Respiratory and Conjunctiva
Publication
Vitamin D Levels and SARS-CoV-2 Infection among Medically Underserved Populations in the Minority and Rural Coronavirus Insights Study

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2026 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only. May include AI-generated and/or AI-modified imagery.